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Abstract: Human immunodeficiency virus (HIV) infections and less-than-optimal care of people
living with HIV (PLHIV) continue to challenge public health and clinical care organizations in
the communities that are most impacted by HIV. In the era of evidence-based public health, it is
imperative to monitor viral load (VL) in PLHIV according to global and national guidelines and
assess the factors associated with variation in VL levels. Purpose: This study had two objectives—(a)
to describe the levels of HIV VL in persons on antiretroviral therapy (ART), and (b) to analyze the
significance of variation in VL by patients’ demographic and clinical characteristics, outcomes of HIV
care, and geographic characteristics of HIV care facilities. Methods: The study population for this
quantitative study was 49,460 PLHIV in the Democratic Republic of Congo (DRC) receiving ART
from 241 CDC-funded HIV/AIDS clinics in the Haut-Katanga and Kinshasa provinces of the DRC.
Analysis of variance (ANOVA) was performed, including Tamhane’s T2 test for pairwise comparisons
using de-identified data on all patients enrolled in the system by the time the data were extracted for
this study by the HIV programs in May 2019. Results: The VL was undetectable (<40 copies/mL) for
56.4% of the patients and 24.7% had VL between 40 copies/mL and less than 1000 copies per mL,
indicating that overall, 81% had VL < 1000 and were virologically suppressed. The remaining 19%
had a VL of 1000 copies/mL or higher. The mean VL was significantly (p < 0.001) higher for males
than for females (32,446 copies/mL vs. 20,786, respectively), persons <15 years of age compared to
persons of ages ≥ 15 years at the time of starting ART (45,753 vs. 21,457, respectively), patients who
died (125,086 vs. 22,090), those who were lost to follow-up (LTFU) (69,882 vs. 20,018), those with
tuberculosis (TB) co-infection (64,383 vs. 24,090), and those who received care from urban clinics
(mean VL = 25,236) compared to rural (mean VL = 3291) or semi-rural (mean VL = 26,180) clinics
compared to urban. WHO clinical stages and duration on ART were not statistically significant at
p ≤ 0.05 in this cohort. Conclusions: The VL was >1000 copies/mL for 19% of PLHIV receiving
ART, indicating that these CDC-funded clinics and programs in the Haut-Katanga and Kinshasa
provinces of DRC have more work to do. Strategically designed innovations in services are desirable,
with customized approaches targeting PLHIV who are younger, male, those LTFU, with HIV/TB
co-infection, and those receiving care from urban clinics.

This article is an open access article
distributed under the terms and
conditions of the Creative Commons

Keywords: HIV viral load suppression; antiretroviral therapy; Democratic Republic of Congo;
TB/HIV co-infection; WHO clinical stages

Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).

Healthcare 2022, 10, 69. https://doi.org/10.3390/healthcare10010069

https://www.mdpi.com/journal/healthcare

Healthcare 2022, 10, 69

2 of 11

1. Introduction
With the advancement of technology and science, HIV has transitioned from a lifethreatening terminal illness to a manageable chronic disease. In order for patients to
have an overall good prognosis, HIV prevention programs have to assess and address
the severity of infection by relying on regular measurements of viral load (VL), which is
described as the number of copies of HIV RNA in a milliliter of blood [1]. VL suppression
is the most important milestone on the continuum of HIV care in the era of undetectable
equals untransmittable (U = U) [2]. According to the Centers for Disease Control and
Prevention (CDC) data, an HIV-positive patient is considered to be virally suppressed
and at “effectively no risk” of transmission to an HIV-negative person when the VL is
considered “durably undetectable” and remains undetectable for at least six months after
the first undetectable result [3,4]. Both the CDC and the World Health Organization
(WHO) recognize and promote the benefits of ART for VL suppression in PLHIV [5,6].
The WHO also recommends that VL monitoring be regularly conducted after PLHIV are
placed on ART, with first the VL test at six months after ART initiation and annual testing
thereafter [7].
To eradicate HIV/AIDS by 2030, the Joint United Nations Program on HIV and
AIDS (UNAIDS) developed goals that focus on diagnosis, therapy, and viral suppression.
UNAIDS has set 95–95–95 targets to be met by the year 2030 [8]. Globally in 2019, data show
that only 31% of PLHIV that are receiving ART are virally suppressed. In the western and
central regions of Africa, the viral suppression rate is 45% and varies greatly by country [9].
According to the 2020 UNAIDS Report, the Democratic Republic of Congo (DRC) had
achieved 54% of the first 95 (percentage of PLHIV who know their status), and 98% of
the second 95 (percentage of PLHIV that know their status who are on ART). However,
the data regarding PLHIV who are on ART and have suppressed VL (third 95) were not
available [9].
As HIV programs continue to prioritize their efforts in increasing the number of PLHIV
that are receiving ART and subsequently have VL suppression, there is mounting clinical
evidence that increases the recognition that there are many genetic and behavioral factors
that can affect how a person may respond to therapy. Some of these factors include the age
and gender of the patient, whether the patient continues to seek care, disease progression
before ART is initiated, and adherence to the therapy protocol. According to the WHO and
the CDC, the primary determining factor of VL suppression and risk of transmission is
the patient’s adherence to ART. Unfortunately, long-term adherence in low- and middleincome countries (such as the DRC) is met with numerous patient- and program-related
challenges, such as forgetting to take medication, low health literacy, substance abuse,
long wait times at clinics, distance to clinics, and costs of care [7,10]. Although adherence
to ART directly influences viral suppression, some patients with long-term adherence
to ART are also experiencing viral rebound due to either suboptimal adherence after a
period of good adherence or ART-resistant mutations [11,12]. ART interruption is also
known as interruption in treatment (IIT). IIT is another critical issue for HIV prevention
and management programs because it not only increases the risk of HIV spread, but PLHIV
experiencing IIT also tend to have poorer outcomes, such as a higher risk of mortality
compared to those that have not experienced IIT [13].
Previous studies have shown that there are differences in VL based on gender; women
have been shown to have significantly lower VL than men, and the differences have been
attributable to hormone levels and plasma HIV RNA thresholds [14–17]. Additional studies
have also shown that children (18 months to 18 years of age) were more likely to reach
viral suppression than adults, which can be attributed to children being less likely to
experience IIT because they often visit vaccination clinics, their growth may be monitored
regularly, and parents may continue to bring children to clinics for treatment [18,19]. The
studies also reported that older adults (65 years and older) were more likely to achieve
VL suppression than younger adults [2,18,20]. However, the gender and age differences
diminish at later stages of the disease [15–17,21,22]. Thus, researchers have recommended
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that providers ensure that ART is being administered appropriately based on gender, age,
and CD4 counts [14–16].
Efficient program planning and strategic priority-setting in HIV clinical care programs
require systematic assessment and evaluation of the outcomes in the populations served
by the programs. An important objective of such data-driven assessments is to generate
evidence of change in HIV patient outcomes and to assess the positive impact of clinical
services over time. To that end, this study had two objectives—to examine the levels of HIV
VL in persons on ART, and to analyze factors associated with variation in VL, including
patients’ demographic and clinical characteristics, outcomes of HIV care such as death
and LTFU, and rurality–urbanicity of HIV care clinics. In the DRC, the HIV programs are
mainly funded by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) and the
Global Fund. The national HIV/AIDS program coordinates HIV service activities.
2. Materials and Methods
2.1. Data
This study utilized secondary data received from the National HIV/AIDS Program
(PNLS). The PNLS managed the HIV clinics with the support of CDC/PEPFAR implementing partners. The study population for this quantitative study was 49,460 PLHIV
receiving ART from 241 CDC-funded HIV/AIDS clinics in the Haut-Katanga and Kinshasa
provinces of the DRC. The de-identified dataset comprised all patients enrolled in these
241 HIV programs at the time of data extraction in May 2019, with ART initiation dates
from 2014 to 2019. The clinical database of HIV counseling, testing, and service delivery is
maintained for these clinics using a national electronic records system for patient management, TIER.Net (accessed on 21 June 2021). The original data were collected under local
IRB approval No. ESP/CE/229/2019 by FHI 360. Georgia Southern University (protocol
number HI 9260) exempted this research from a full IRB review.
2.2. Dependent Variable
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The dependent variable viral load (VL) was recorded in the database as the number of
copies of HIV RNA in a milliliter of blood at the time of the last VL test. This continuous
variable was used as the primary outcome measure for its univariate associations with
independent variables. In addition, for the graphical depiction of the VL in ranges of
interest to HIV programs, the following ranges were computed (as displayed in Figure 1):
<40 copies/mL, 40 to <50 copies, 50 to <200 copies, 200 to <400 copies, 400 to <1000 copies,
4 of 12
and 1000 or more copies/mL of blood [9,12].

Figure 1. Percent distribution of persons on antiretroviral therapy by viral load levels in HIV/AIDS
clinics of Haut-Katanga
Kinshasa provinces,
Democratic on
Republic
of Congo, 2014–2019.
Figure
1. Percentand
distribution
of persons
antiretroviral
therapy by viral load levels in HIV/AIDS
clinics
of Haut-Katanga
and Kinshasa provinces, Democratic Republic of Congo, 2014–2019.
2.3. Independent
Variables

The dichotomous variable TB/HIV co-infection was coded as “TB present” and “TB
not present,” whereas records with codes 0 and 1 were excluded from our analysis. The
variable patient outcome death was coded as 1 “died” and 2 “in care, transferred out, or
LTFU.” The variable WHO Stages had four attributes: stage 1 (asymptomatic), stage 2
(mildly symptomatic), stage 3 (moderately symptomatic), and stage 4 (severely symptomatic). The variable ART initiation mode had two categories: “new patient” and “trans-
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2.3. Independent Variables
The dichotomous variable TB/HIV co-infection was coded as “TB present” and “TB not
present,” whereas records with codes 0 and 1 were excluded from our analysis. The variable
patient outcome death was coded as 1 “died” and 2 “in care, transferred out, or LTFU.”
The variable WHO Stages had four attributes: stage 1 (asymptomatic), stage 2 (mildly
symptomatic), stage 3 (moderately symptomatic), and stage 4 (severely symptomatic). The
variable ART initiation mode had two categories: “new patient” and “transferred in.” The
variable duration on ART was computed by computing the time difference between “date
of the last visit for ART” and “ART start date.” For our analysis, the variable duration on
ART was recoded into quartiles, with the following categories: “<3.23 months,” “3.23 to
14.52 months,” “14.53 to 40.37 months,” and “>40.37 months.” Two demographic variables
were patient sex, with the categories “male” and “female,” and age at the time of the start of
ART, with the attributes shown in Table 1. Province of health facility location (Haut-Katanga
and Kinshasa) and rurality/urbanicity status of the health zone were the two geographic
variables. The variable rurality/urbanicity consisted of three categories based on the health
zone—“rural,” “semi-rural,” and “urban,” as identified by the population density in cities
or towns within the zone.
Table 1. Descriptive statistics for characteristics of patients in HIV/AIDS clinics of Haut-Katanga
and Kinshasa provinces, DRC, 2014–2019.
Patient Characteristics

Number

Percent (%)

15,326
32,134

31.0
69.0

Sex
Male
Female
Age at the Time of Start of ART
<15 years of age
15 years or older
Age and Sex
<15 years, male
<15 years, female
15 years or older, male
15 years or older, female

4769
41,454

10.3
89.7

2243
2526
12,126
29,328

4.9
5.5
26.2
63.4

Patient Outcome—Death
In care, transferred out or LTFU
Died

46,609
2851

94.2
5.8

Patient Outcome—LTFU
In care or transferred out
LTFU

38,872
7737

83.4
16.6

TB Status
No TB
TB present

43,218
1631

96.4
3.6

WHO Stage
Stage 1
Stage 2
Stage 3
Stage 4

18,515
10,116
13,565
1960

41.9
22.9
30.7
4.4

ART Initiation Mode
New patient
Transferred in

44,060
2214

95.2
4.8
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Table 1. Cont.
Patient Characteristics

Number

Percent (%)

Duration on ART in Months
Less than 3.23 months
3.23 to 14.52 months
14.53 to 40.37 months
More than 40.37 months

11,566
11,540
11,549
11,542

25.0
25.0
25.0
25.0

Province
Haut-Katanga
Kinshasa

14,596
34,864

29.5
70.5

Rurality/Urbanicity Status
Rural
Semi-rural
Urban

2790
5780
40890

5.6
11.7
82.7

Abbreviations: TB, Tuberculosis; WHO, World Health Organization; ART, antiretroviral therapy; LTFU, lost to
follow-up.

2.4. Analytical Methods
We computed descriptive statistics—frequencies and percentages—for the dependent
variable and all independent variables. To assess the associations of categorical independent
variables with the VL as the continuous dependent variable, we performed analysis of
variance (ANOVA). We also performed multiple comparison tests for independent variables
with more than two categories if the p-value for ANOVA was ≤0.05, indicating that at
least one pair of categories for an independent variable differed significantly in mean VL.
The pairwise multiple comparisons were included in the analysis to identify which pairs
of categories of each independent variable had significantly different mean VL. Because
the assumption of equal variance was violated during the ANOVA test, the pairwise
comparisons were based on the statistics of Tamhane’s T2 [23]. The outcome variable was
found to be normally distributed, and equality of variance was assumed based upon the
results of Leven’s test. All analyses for this study were performed using IBM SPSS Statistics
version 25.0 (IBM Corporation, Armonk, NY, USA) [24].
3. Results
The VL in 56.4% of the patients was undetectable (i.e., <40 copies/mL), whereas 19.0%
had the heaviest VL of 1000 copies or higher count per mL (Figure 1). The VL was 40 to
<50 copies/mL for 7.4%, 50 to <200 copies/mL for 6.6%, 200 to <400 copies/mL for 2.7%,
and 400 to <1000 copies/mL for 7.9% of the patients.
Descriptive statistics for patients receiving ART at HIV/AIDS clinics (Table 1) show
that 69.0% were female, and 89.7% were 15 years or older. Death was the outcome for 5.8%
of patients, as opposed to 94.2% who remained in care, were transferred out, or had therapy
interruption (LTFU). After excluding those who died, 16.6% were LTFU, as opposed to
83.4% who remained in care or were transferred out. TB/HIV co-infection existed in 3.6%
of the patients. The highest proportion of patients, 41.9%, were in the WHO’s stage 1 of
disease progression, whereas 22.9%, 30.7%, and 4.4% were in stages 2, 3, and 4, respectively.
Most of the patients initiating ART therapy (95.2%) were new patients. Other trends in
patient characteristics are displayed in Table 1.
The results of the one-way ANOVA test performed to compare the mean VL by
patient characteristic (Table 2) show that mean VL was significantly higher for males than
for females (32,446 copies/mL vs. 20,786; p < 0.001, respectively). The mean VL was
significantly higher in patients less than 15 years of age (45,753 vs. 21,457; p < 0.001).
The age–sex interaction variable had a significant association with VL (p < 0.001); specific
multiple comparisons for this and other non-dichotomous variables are discussed in the
next paragraph. Patients who died had a much higher VL than those still alive (125,086 vs.
22,090; p < 0.001, respectively). The mean VL for patients who were LTFU was significantly
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higher than for those in care or transferred out (69,882 vs. 20,018, p < 0.001, respectively).
Patients with TB co-infection also had a significantly higher mean VL of 64,383 copies
per mL compared to 24,090 in those without TB co-infection (p < 0.001). A statistically
significantly higher (p < 0.001) mean VL existed in patients from Kinshasa compared to
those from Haut-Katanga (31,541 vs. 8021, respectively). Mean VL significantly differed by
rurality levels of the health zones, with a mean VL of 3291 for rural health zones and 25,236
for urban (p < 0.001). WHO clinical stages and ART were not statistically significant in this
cohort.
Table 2. Analysis of variance (ANOVA) results for the association of characteristics of patients with
viral load in HIV/AIDS clinics of Haut-Katanga and Kinshasa provinces, DRC, 2014–2019.
Patient Characteristics

Number

Mean

Sex
Male
Female

4395
10,738

Age at the Time of Start of ART
<15 years of age
15 years or older

95% CI
Lower

Upper

32,446
20,786

26,234
17,955

38,658
23,617

1694
13,436

45,753
21,457

36,270
18,663

55,237
24,252

Age and Sex
<15 years, male
<15 years, female
15 years or older, male
15 years or older, female

798
896
3594
9842

50,536
41,494
28,457
18,901

36,954
28,240
21,488
16,059

64,119
54,747
35,425
21,743

Patient Outcome—Death
In care, transferred out, or LTFU
Died

14,827
306

22,090
125,086

19,428
92,125

24,752
158,047

Patient Outcome—LTFU
In care or transferred out
LTFU

14,211
616

20,018
69,882

17,532
41,518

22,505
98,247

TB Status
No TB
TB present

14,226
343

24,090
64,383

21,271
41,881

26,909
86,884

WHO Stage
Stage 1
Stage 2
Stage 3
Stage 4

5026
3232
4894
644

19,568
25,212
25,826
34,336

15,439
17,729
21,620
18,019

23,698
32,696
30,031
50,652

ART Initiation Mode
New patient
Transferred in

13,944
1188

25,471
8958

22,555
5523

28,386
12,392

Duration under ART in Months
Less than 3.23 months
3.23 to 14.52 months
14.53 to 40.37 months
More than 40.37 months

91
1804
5695
7535

48,761
21,219
22,860
25,571

-21
15,595
17,982
21,872

97,542
26,842
27,739
29,271

Province
Haut-Katanga
Kinshasa

4741
10,392

8021
31,541

5403
27,802

10,639
35,280

Rurality/Urbanicity
Rural
Semi-rural
Urban

821
2038
12,274

3291
26,180
25,236

1351
18,080
22,193

5231
34,281
28,279

p
<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

0.09

<0.001

0.35

<0.001

<0.001

Abbreviations: CI, confidence interval; TB, tuberculosis; WHO, World Health Organization; ART, antiretroviral
therapy; LTFU, lost to follow-up. Note: Bolded p-values indicate the significance of differences at p < 0.05.
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Multiple comparison analysis for independent variables with more than two categories
(Table 3) tested the significance of mean VL differences across multiple attributes of those
independent variables. Post-hoc comparison using Tamhane indicated that the mean VL
for <15-year-old males was significantly higher than for males 15 years or older (mean
difference (MD), 22,080 copies per mL) and females 15 years or older (MD, 31,636 copies
per mL). The mean VL for <15-year-old females was also significantly higher than females
15 years or older (MD, 22,593 copies per mL). Although urban vs. semi-rural facilities did
not differ significantly, urban vs. rural (MD, 21,945) and semi-rural vs. rural (MD, 22,890)
location of clinics showed statistically significant differences in mean VL (p < 0.001).
Table 3. Multiple comparisons of mean viral loads from ANOVA for independent variables with
>2 categories in HIV/AIDS clinics of Haut-Katanga and Kinshasa provinces, DRC, 2014–2019.
95% CI

Mean
Difference

Lower

Upper

<15 years, female
15 years or older, male
15 years or older, female

9043
22,080
31,636

−16,425
1581
12,993

34,511
42,578
50,278

0.92
0.03
<0.001

<15 years, male
15 years or older, male
15 years or older, female

−9043
13,037
22,593

−34,511
−7068
4384

16,425
33,142
40,801

0.92
0.42
<0.001

<15 years, male

−22,080

−42,578

−1581

0.03

<15 years, female
15 years or older, female

−13,037
9556

−33,142
−547

7068
19,659

0.42
0.07

<15 years, male

−31,636

−50,278

−12,993

<0.001

<15 years, female
15 years or older, male

−22,593
−9556

−40,801
−19,659

−4384
547

0.01
0.07

Semi-rural
Urban

−22,890
−21,945

−33,038
−26,340

−12,741
−17,550

<0.001
<0.001

Semi-rural

Rural
Urban

22,890
945

12,741
−9598

33,038
11,487

<0.001
1.00

Urban

Rural
Semi-rural

21,945
−945

Subgroups
Age and Sex
<15 years, male

<15 years, female

15 years or older,
male

15 years or older,
female

Rurality/Urbanicity
Status
Rural

p-Value

17,550
26,340
<0.001
−11,487
9598
1.00
Abbreviations: CI, confidence interval. Note: Bolded p-values indicate the significance of differences at p < 0.05.

4. Discussion
This research aimed to assess the HIV VL and factors associated with variation in VL
among PLHIV using data from the DRC’s National HIV/AIDS Program (PNLS). Our study
findings regarding VL distribution will assist HIV prevention and therapy programs in
the DRC to predict prognosis, classify disease progression, assess therapy success, and
evaluate the risk of HIV transmission to others. In our study population, the last tested VL
was undetectable (<40 copies/mL) for the majority (56.4%) of the patients, whereas roughly
one-quarter (24.7%) had a VL between 40 copies/mL and less than 1000 copied per mL.
Since 19% had a VL of 1000 or higher, this indicates that cumulatively, 81% had a VL < 1000
and were virologically suppressed. Other recent studies in Sub-Saharan Africa countries,
such as Rwanda and Malawi, showed that up to 88% to 91% of persons on ART had a
VL < 1000 [25,26]. In our study, a relatively lower proportion of PLHIV with a suppressed
VL may indicate therapy gaps, which would call for evaluations by the HIV programs in
the DRC to strategically revisit their therapy and coordinated services. Yet, the differences
shown could be attributable to a different mix of study samples with respect to factors that
can affect VL.
Our study findings on the distribution of patients by the WHO clinical stages showed
that 30.7% of patients were in stage 3 and 4.4% were in stage 4. Because PLHIV at these
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moderately to severely symptomatic stages are at much higher risk of poor outcomes, our
findings of variation in VL by specific WHO stages may inform any therapy customization
effort for specific disease progression stages.
Our findings of significantly higher VL for patients who were younger than 15 years
of age at the start of ART may mean that onset and diagnosis of the infection at an early
age may result in greater difficulties in managing the disease. A more in-depth future
study may provide specific research evidence. Our study also showed that mean VL was
significantly higher for males than for females, which is consistent with the existing body
of literature, and is thought to be due to differences in hormone levels, plasma and HIV
RNA thresholds, and lower likelihood to access health services, meaning that males may be
diagnosed later in their disease progression [14–17]. However, it may also be because, in the
DRC, women have more points of entry to care and are more likely to seek care. Thus, their
familiarity with more service points providing care may also improve their chances of early
referrals to HIV prevention and management programs. We also noted that males who
were on ART before age 15 had much higher VL compared to males or females in other age
groups, potentially pointing to a synergetic effect of early-onset/diagnosis and being a male.
Our study also showed that there was no association between the duration of ART and VL,
perhaps due to the complexity of this relationship. Although adherence to ART is known
to improve VL, the risk of therapy interruptions increases with longer duration on ART,
particularly in resource-challenged environments, which can be associated with patientand/or program-related challenges [7,10]. Our analysis of mean VL by the interaction
of age at the start of ART and duration in ART showed that the worst VL levels existed
in patients who started ART at ages <15 years and had been on ART for >40.37 months,
a difference of 32,762 copies/mL compared with those who had started ART when they
were 15 years old or older and the ART duration was 3.23 to 14.52 months. Unfortunately,
patients who began ART some time ago may have started with a less effective regimen,
thus allowing their disease to progress to more advanced stages before the availability of
new, more effective regimens.
Our results show that therapy interruption (LTFU) has severely negative consequences
for HIV VL management, calling for special attention from HIV programs to aim to improve
their patient retention performance. Our findings indicate that the arithmetic mean VL
for those in care or transferred out to another care facility was 20,018 copies per mL, a
stark contrast to the mean VL for those with therapy interruption indicated by LTFU
(69,882 copies per mL). Therefore, the strategies to reduce the IIT must be proactively and
collaboratively devised by HIV prevention and management programs in order to prevent
poor health outcomes such as death and/or the risk of HIV transmission [13,27]. One
strategy to reduce the risk of IIT could be maintaining interoperable patient information
systems, ongoing data sharing across health facilities, and ongoing data linkage to detect the
patients who are LTFU at a facility but seek treatment at another facility. Another strategy
is to implement decentralized drug distribution (DDD) models where ART patients can
receive their medication refills in a community setting instead of at the health clinic. Multimonth dispensing may also increase the chances of retention in care, because compliant
patients do not need to return often to the facility for medication pick-up. Data linkage
with other social services databases may also reduce the risk of IIT. In a recent cohort
study, interventions that included longer periods between ART refills (i.e., multi-month
dispensation), home delivery of ART refills, linkage to social service support programs
after diagnosis, and “silent” transfer of care between clinics for patients relocating (e.g., due
to change in employment) were all possible successful strategies for increasing retention in
care and preventing the potential for therapy interruption [28].
We found that the mean VL was significantly lower for patients seeking care at rural
clinics than semi-rural or urban locations. Urban patients also have more options and may
move more frequently to other clinics, interrupting their care and being listed as lost to
follow-up in the absence of a unique identifier in clinical HIV care systems. Lower levels
of VL in rural areas may be primarily due to the patterns of care-seeking by the severity
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of illness, with the sickest rural residents seeking care in urban areas. Even in semi-rural
areas, the trend is for the sickest patients to move to urban areas with better-equipped and
better-staffed facilities. Rural communities are often more closely knit, so the social stigma
often associated with HIV may motivate the sickest rural residents to seek HIV care from
urban centers away from their communities. On the other hand, in rural locations, the
patients tend to have closer relationships with their healthcare providers, and patients may
therefore have better adherence to healthcare providers’ instructions.
This quantitative study has some limitations; therefore, our findings should be interpreted within the context of these limitations. First, the secondary data did not contain
repeated measures of the VL. In the absence of these data, VL from the last virological
test was used. Were all measures of VL available for the period of study, it would have
been beneficial to analyze patterns of VL changes and rebounds. Secondly, our choice of
variables was limited to a small number of variables captured in the program data and
shared with the research team. There are many socio-economic and lifestyle measures not
captured in the dataset, which may explain the variation in VL. Finally, our data did not
include information concerning the history of a patient having received enhanced adherence counseling, which may have influenced therapy adherence and, in turn, VL levels. In
addition, data for other comorbidities were also not available, meriting a suggestion that
future studies should also focus on the comorbidity profile of the patients. Regardless of
these limitations, our findings are generalizable to HIV services in the DRC.
5. Conclusions
Evidence-based continuous quality improvement is increasingly deemed essential
for public health services, including HIV prevention, as is management services being
efficient in the face of increasing demands and shrinking resources [29]. The current study
produced practice-relevant research evidence showing that although 81% of the PLHIV who
were on ART had their VL suppressed below <1000 copies/mL, the clinics and programs
offering these services in the Haut-Katanga and Kinshasa provinces of the DRC have more
work to do. Strategically designed innovations in services, with better collaborations with
community partners for referrals, are desirable to come closer to the target of 95% of all
people receiving ART to have viral suppression and working towards the elimination of
the AIDS epidemic. Our research findings concerning risk for un-suppressed VL suggest
that innovation in the efficient delivery of services to all PLHIV is even more essential
during the COVID-19 pandemic and in the post-pandemic era, because some public health
and healthcare resources have been reallocated to address the emergent COVID-19 care
needs, and in some settings, layering of chronic non-communicable services is becoming
necessary to deal with resource shortages [29].
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